FIRST AIRED: June 26, 2017

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



>> Martin Shkreli, the former pharmaceutical CEO, vilified for jacking up the price of a lifesaving drug, arriving at Brooklyn Federal Court Monday. The boyish 34-year-old dubbed pharma bro is facing charges he ran a ponzi like scheme at a hedge fund. Prosecutors say he misled investors about the funds performance then repaid investors with money siphoned from another firm, Shkreli's pleaded not guilty.
Reuter's legal correspondent, Brendan Pierson.>> Now we don't know exactly what Shkreli's defense is going to look like, but from what his lawyer said in court, he's gonna try to portray himself as a boy genius. A scientifically-minded person rather than a financier, who his investors trusted for his scientific acumen.
>> The securities fraud charges stem from actions Shkreli allegedly undertook before he became the CEO of Turing Pharmaceutical, where he briefly enjoyed a reputation as one of the most reviled people in America.>> Martin Shkreli first came to public attention in 2015 when he raised the price of a life saving drug by more than 5,000%.
He stayed a controversial figure after that, defending his actions in social media and sometimes bragging about his wealth. Talking about a Picasso painting he owns, a $2 million one of a kind Wu-Tang Clan album he bought, and clashing with journalists on social media. Eventually he was banned from Twitter in January for harassing a female journalist who criticized Donald Trump.
>> Shkreli faces up to 20 years in prison if convicted of securities fraud.